Stocks Close Off Day's Lows; Vipshop Jumps
at Investor's Business Daily - 1 hr 1 min ago
Stocks racked up another session of losses Thursday amid lackluster data on industrial production and housing, but they finished off the day's worst levels. The S&P 500 dropped 0.9%, marking its third straight loss. But it closed above its 50-day...
Why WuXi PharmaTech (Cayman), Inc. (ADR) Shares Crashed
Alex Planes, The Motley Fool - Motley Fool - 2 hrs 39 mins ago
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of WuXi PharmaTech have fallen more than 14%...
Stocks Down In Afternoon; HollySys Triggers Sell Rule
at Investor's Business Daily - Thu May 15, 12:29PM CDT
The major averages were hitting new session lows early Thursday afternoon as weak economic data raised concerns about the health of the economy. The Nasdaq was down 1.2%, the S&P 500 fell 1.1% and the Dow Jones industrial average sank 1.0%. Volume on...
Stocks Head South In Firm Trade; Arctic Cat, Bristol Myers Tumble
at Investor's Business Daily - Thu May 15, 9:36AM CDT
Stocks rumbled lower in fat trade Thursday, as weak readings on factory output and housing overshadowed more positive data. The Nasdaq veered 1.4% lower while the S&P 500 shed 1.1% and the Dow Jones industrial average lost 0.9%. Options expirations...
WUXI PHARMATECH
at Investor's Business Daily - Wed May 14, 5:40PM CDT
WUXI PHARMATECH (WX) said Q1 EPS fell 14% to 30 cents, missing views by 9 cents. Revenue rose 11% to $146.7 mil, above. The Chinese contract research organization sees Q2 EPS of 46-48 cents, under views for 49 cents. Shares fell 6.6% to 34.
Cisco, Vipshop Up After-Hours On Earnings Surprises
at Investor's Business Daily - Wed May 14, 4:14PM CDT
Shares of Cisco Systems (CSCO) and Vipshop Holdings (VIPS) climbed after the close Wednesday as both companies topped profit expectations. The positive results were a contrast to a forgettable regular session in the stock market today, when selling...
WuXi PharmaTech Announces First-Quarter 2014 Results
PR Newswire - Wed May 14, 3:30PM CDT
WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading research and development services company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for the first quarter of 2014.
Dow, S&P Hit Records, But End Little Changed
at Investor's Business Daily - Tue May 13, 4:00PM CDT
Stocks wavered to a narrowly mixed finish in the stock market today. The Dow Jones industrial average rose 0.1% and the S&P 500 ticked up a fraction. Both hit record highs. They were up as much as 0.2% and 0.3%, intraday. The Nasdaq slipped 0.3%,...
WuXi PharmaTech Completes Construction of New Biosafety Testing Facility in Suzhou
PR Newswire - Tue May 13, 7:00AM CDT
WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced that construction has been completed on a new biologics biosafety testing facility in Suzhou.
WuXi PharmaTech Completes Construction of New Materials Characterization Facility in St. Paul
PR Newswire - Mon May 12, 7:00AM CDT
WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, announced today that it has completed an expansion of its materials characterization testing facility in St. Paul, Minnesota.
WuXi PharmaTech Begins Construction of New R&D and cGMP Manufacturing Campus in Changzhou
PR Newswire - Thu May 08, 7:26AM CDT
WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device research and development (R&D) services company with operations in China and the United States, today announced that its manufacturing subsidiary, Syn-The-All (STA) Pharmaceuticals Co., Ltd., has begun construction of a new, fully integrated R&D and cGMP manufacturing site in Changzhou, about 110 miles west of Shanghai. The new construction aims to meet the rapidly growing demand for WuXi's manufacturing services, which have quadrupled their revenues in the past four years.
Earnings Results, Esteemed Recognitions, and Conference Call Schedules - Analyst Notes on Covance, Alere, LabCorp, Charles River and WuXi PharmaTech
PR Newswire - Thu May 08, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Covance Inc. (NYSE: CVD), Alere Inc. (NYSE: ALR), Laboratory Corp. of America Holdings (NYSE: LH), Charles River Laboratories International, Inc. (NYSE: CRL) and WuXi PharmaTech (Cayman) Inc. (NYSE: WX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2179-100free.
FDA Approves Ibalizumab Manufactured by WuXi PharmaTech for Treatment of Patients on Expanded Access
PR Newswire - Mon May 05, 7:00AM CDT
WuXi PharmaTech (NYSE: WX) and TaiMed Biologics today announced that the FDA has approved the first batch of the ibalizumab (TMB-355) drug substance and sterile drug product manufactured at WuXi's biologics facilities for ongoing treatment of patients under investigator-sponsored IND's. This is the first reported FDA approval of a sterile biologics product manufactured in China for use under a U.S. IND, which marks an important milestone of WuXi's investment to expedite global development of innovative biologics.
Earnings Beat at Endo, Shares Up on Improved Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 02, 11:10AM CDT
Endo (ENDP) beat on earnings in the first quarter.
3 Leading Chinese Stocks Among Top Mutual Fund Buys
at Investor's Business Daily - Thu May 01, 9:45PM CDT
Mutual funds and other big institutions account for the lion's share of stock trades. Today's Screen Of The Day is Accelerating Mutual Fund Accumulation, which lists companies, such as WuXi PharmaTech (WX), that big funds are piling into. Today's...
QLT Widens Loss in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 10:40AM CDT
Loss at QLT (QLTI) widened due to higher costs.
WuXi PharmaTech Receives 2013 Lilly Global Supplier Award
PR Newswire - Thu May 01, 7:00AM CDT
WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced that the company has received the 2013 Lilly Global Supplier Award. This is the third time that WuXi has been honored with this award from Eli Lilly and Company. This award was established to recognize the exceptional efforts of Lilly's suppliers in providing the company with a competitive advantage. The honor recognizes WuXi AppTec's contributions to Lilly's drug development programs.
Auxilium Pharma Cuts Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 4:20PM CDT
Auxilium Pharma lowered its guidance for 2014 and cut its revenue guidance by $70 million to $380 million - $420 million.
WuXi PharmaTech Facilities for Late- and Commercial-Stage Analytical and Stability Testing and Clinical-Trial Materials Manufacturing Pass FDA Audit
PR Newswire - Wed Apr 30, 7:00AM CDT
WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced that its analytical and stability testing facilities, located in Shanghai Waigaoqiao Free Trade Zone, have successfully passed an FDA general GMP inspection. This achievement brings regulatory advantages and potential expedited approval to clients who use these WuXi services for their NDA/ANDA filings and commercial analytical and stability testing. The clinical trial materials manufacturing for drug products (CTM), packaging and labeling facilities were also inspected and found to be in compliance.
WuXi PharmaTech Breaks Ground on New Cell Therapy Manufacturing Facility
PR Newswire - Tue Apr 29, 7:23AM CDT
WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced that it has broken ground on a new facility in Philadelphia for the manufacture of cell therapies. The facility is expected to become operational in the second quarter of 2015.